These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12848966)

  • 21. B lymphocytes in nonorgan-specific autoimmune diseases: implications for therapy.
    Youinou P; Pers JO
    Lupus; 2012 Nov; 21(13):1375-7. PubMed ID: 22976931
    [No Abstract]   [Full Text] [Related]  

  • 22. To B or not to B: TNF family signaling in lymphocytes.
    Siegel RM; Lenardo MJ
    Nat Immunol; 2001 Jul; 2(7):577-8. PubMed ID: 11429537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New therapeutic approaches to autoimmune diseases].
    Amoura Z; Piette JC
    Presse Med; 2006 Apr; 35(4 Pt 2):709-13. PubMed ID: 16614619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-ligation of surface IgM and CD40 on naive B lymphocytes generates a blast population with an ambiguous extrafollicular/germinal centre cell phenotype.
    Wheeler K; Gordon J
    Int Immunol; 1996 Jun; 8(6):815-28. PubMed ID: 8671671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.
    Chen D; Ireland SJ; Davis LS; Kong X; Stowe AM; Wang Y; White WI; Herbst R; Monson NL
    J Immunol; 2016 Feb; 196(4):1541-9. PubMed ID: 26764035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody production in autoimmune BXSB mice. I. CD40L-expressing B cells need fewer signals for polyclonal antibody synthesis.
    Blossom S; Gilbert KM
    Clin Exp Immunol; 1999 Oct; 118(1):147-53. PubMed ID: 10540172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin.
    Benoit NE; Wade WF
    Immunopharmacology; 1996 Nov; 35(2):129-39. PubMed ID: 8956976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel opportunities for therapeutic targeting in systemic autoimmune diseases.
    Ouarzane M; Zouali M
    Methods Mol Biol; 2007; 361():285-97. PubMed ID: 17172718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells.
    Fletcher CA; Sutherland AP; Groom JR; Batten ML; Ng LG; Gommerman J; Mackay F
    Eur J Immunol; 2006 Sep; 36(9):2504-14. PubMed ID: 16906535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.
    Mackay F; Woodcock SA; Lawton P; Ambrose C; Baetscher M; Schneider P; Tschopp J; Browning JL
    J Exp Med; 1999 Dec; 190(11):1697-710. PubMed ID: 10587360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ISCCA flow protocol for the monitoring of anti-CD20 therapies in autoimmune disorders.
    Gatti A; Buccisano F; Scupoli MT; Brando B
    Cytometry B Clin Cytom; 2021 Mar; 100(2):194-205. PubMed ID: 32598578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis.
    Mongini PK; Jackson AE; Tolani S; Fattah RJ; Inman JK
    J Immunol; 2003 Nov; 171(10):5244-54. PubMed ID: 14607925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B cell targeted therapies in autoimmune disease.
    Barnas JL; Looney RJ; Anolik JH
    Curr Opin Immunol; 2019 Dec; 61():92-99. PubMed ID: 31733607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of BAFF in immune function and implications for autoimmunity.
    Kalled SL
    Immunol Rev; 2005 Apr; 204():43-54. PubMed ID: 15790349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-cell-directed therapy: which B cells should be targeted and how?
    Yamamura T; Miyake S
    Immunotherapy; 2012 May; 4(5):455-7. PubMed ID: 22642324
    [No Abstract]   [Full Text] [Related]  

  • 38. CD40 signaling and autoimmunity.
    Cheng G; Schoenberger SP
    Curr Dir Autoimmun; 2002; 5():51-61. PubMed ID: 11826760
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting B cells in treatment of autoimmunity.
    Franks SE; Getahun A; Hogarth PM; Cambier JC
    Curr Opin Immunol; 2016 Dec; 43():39-45. PubMed ID: 27718447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The therapeutic potential of anti-CD20 "what do B-cells do?".
    Eisenberg R; Looney RJ
    Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.